Vanda Pharmaceuticals secured FDA approval for Nereus in December 2025, positioning the company to address an estimated $1.2 billion global motion sickness market. The label covers prevention of vomiting and nausea during travel, with launch anticipated in Q1 2026. Management forecasts peak annual sales of $150 million in the United States, driven by a combination of physician detailing and over-the-counter expansion discussions. This approval also opens a regulatory path for studying Nereus as an adjunct to GLP-1 therapies, where an estimated 40% of patients experience significant nausea.

In the third quarter ended September 30, 2025, Vanda reported Fanapt franchise sales up 18% year-over-year, driven by new psychiatrist onboarding in the U.S. and expanded reimbursement coverage. However, R&D expenses rose 34% to $35.4 million as late-stage trials for Bysanti and a Phase II autoimmune program advanced. SG&A spend increased 28% to $27.2 million, reflecting pre-launch marketing build-out for Nereus. These combined investments resulted in a net loss of $22.6 million, compared with a loss of $12.1 million in the year-ago quarter.

As of September 30, 2025, Vanda held $293.8 million in cash, cash equivalents and marketable securities, providing over three years of runway at current burn rates. The company reiterated its full-year 2025 revenue guidance of $210 million to $230 million, underpinned by steady Fanapt contributions and initial revenue recognition for Nereus. Vanda anticipates that operating expenses will peak in mid-2026 as commercialization activities for two late-stage assets ramp. Management expects to maintain at least $100 million in unrestricted liquidity through the end of 2026.

Vanda’s Bysanti, a novel small molecule targeting refractory depression, is scheduled for a PDUFA decision in July 2026. Analysts estimate peak U.S. sales of $300 million annually, based on a $2.50 per tablet list price and a five‐year treatment duration. Should Bysanti achieve approval, Vanda plans to deploy a targeted specialty sales force of 70 representatives. Beyond 2026, the pipeline includes two Phase III oncology programs and an early‐stage neuroscience candidate, positioning Vanda for multiple potential launches through 2028.